Home
overview

SMi introduces UK & Europe's launch conference; Cell and Gene Therapy, which takes place between the 9th and 11th October 2018.

Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

This year event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.

Join our expert speaker panel at the Cell and Gene Therapy conference to ensure you do not miss out on the latest developments! Presenting new technologies, specific case studies, updates on GMP, MHRA regulatory guidelines, quality control and therapeutic applications of stem cells, pre-clinical and clinical trial design, advanced cell engineering technologies, commercialisation of ATMPs, global pricing, ethical overviews and many more.

Cell and Gene Therapy will be inviting speakers from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions.

Expect over 16 presentations and case studies focused on the key aspects of drug discovery, safety and toxicology assessments, bioprocessing, regulatory frameworks and patient access in the field of cell and gene therapy.

Join our expert speaker panel this October to ensure you do not miss out on the latest developments!

Presenting sessions on:

  • Cell Therapy Research Manufacturing Innovation
  • Global Medical Affairs
  • Regulatory Updates
  • GMP and Quality Control
  • Cell and Tissue Therapies (CART therapies, stem cells, cord blood, preclinical and clinical developments)
  • Regenerative Medicine
  • Advanced Therapy Production
  • Gene Therapy Development
  • Clinical Platform Development
  • Manufacturing and RD of Cell and Gene Therapies

Speakers and delegates will include CEOs, CSOs, CMOs, VPs, Senior and Principle Scientists Researchers, Scientists, Medical Doctors and Professionals in the fields of:


• Drug Discovery & Development
• Personalized , Translational, Stratified, Regenerative and Experimental Medicine
• Cell / Molecular Biology
• Cell / Gene Therapy
• Rare & ultra-rare diseases
• Genetic Diseases
• Ophthalmology
• Cancer / Oncology
• Market Access
• Pricing & Reimbursement
• Patient Advocacy
• Regulatory & Medical Affairs
• Commercial Development
• Bioinformatics
• Big Data
• Digital Health
 

Agenus; Adaptimmune, AstraZeneca; Autolus; BioNTech AG; BTG plc; ccit-denmark; Celerion; Celixir; Exicure Inc.; Hopital Europeen Georges Pompidou; Humacyte; ImmunXperts; INSERM; Institut Universitaire D'hematologie; Janssen Vaccines; KLIFO A/S; Merck Sharp & Dohme Limited; Nektar Therapeutics; Nottingham Trent University; Nouscom SRL; Oncology Experts; Ovacure; Ross University School Of Medicine; Silenseed; St Georges University of London; TCR Solutions; The University Of Hong Kong; University Of Antwerp; University College London; UZ Brussel

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Pamela Tranter

Pamela Tranter, Head of Translational Research Group, UCL
View Bio

9:10 Mitigating the immunogenicity of AAV gene therapy vectors with tolerogenic nanoparticles

Kei Kishimoto

Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.
View Bio

• Cellular and humoral immunity against AAV can affect the safety and efficacy of gene therapy and the ability to re-treat patients later in life
• We have developed synthetic vaccine particles encapsulating rapamycin (SVP-Rapamycin) that have been shown to mitigate immunogenicity against a variety of biologic drugs by inducing tolerogenic dendritic cells and antigen-specific regulatory T cells
• We will present pre-clinical data demonstrating the ability of SVP-Rapamycin to inhibit the formation of anti-AAV antibodies and share data from an ongoing clinical trial of SVP-Rapamycin combined with a therapeutic enzyme
 

9:50 Becoming cell therapy makers - Opportunities and challenges in “in house” manufacturing of cell therapy products

Lior  Raviv

Lior Raviv, Vice President of Development, Pluristem
View Bio

  • Reproducible manufacturing techniques  - the basics of process development
  • The importance of closed and automated manufacturing technologies
  • Data management for improvement of process understanding and control
  • The importance of raw materials management
     
  • 10:30 Morning Coffee

    11:00 Uk and EU regulatory affairs: the MHRA perspective

    Janet Glassford

    Janet Glassford, Quality Assessor , Medicines and Healthcare Products Regulatory Agency (MHRA)
    View Bio

    • What support is available for companies from early in the development process?
    • Designing clinical trials in a way that comes up with the evidence regulators need to accelerate ATMPs
    • Ensuring safety while reducing cost of development: working together with regulators to make the approval process more efficient
    • Impact of Brexit and further initiatives
     

    11:40 Opportunities and Challenges of Translating Cell and Gene Therapies in Academia

    Pamela Tranter

    Pamela Tranter, Head of Translational Research Group, UCL
    View Bio

    • Review of the exciting and diverse pipeline of cell and gene therapy projects within UCL with example case studies.
    • Opportunities for project funding:   internal, public funds, industry partners and University spin outs.
    • Understanding the de-risking and evidence required to support the commercial route forward.
     

    12:20 Networking Lunch

    13:20 Intravitreal rAAV gene therapy approaches for the treatment of retinal disorders

    Mehdi  Gasmi

    Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotechnology
    View Bio

    • Indications that are currently pursued at Adverum Biotechnologies
    • Development of novel AAV capsid targeting the eye
    • Advantages of gene therapy approaches to retinal disorders
     

    14:00 Targeting solid and liquid malignancies with the same CAR

    Peggy Sotiropoulou

    Peggy Sotiropoulou, R&D Manager, Celyad
    View Bio

    • What is an ideal target for CAR T cell therapy?
    • Challenges in targeting solid tumours using CAR T cells
    • Autologous versus allogeneic CAR T cells
     

    14:40 Afternoon Tea

    15:10 Spotlight: Risk-based approaches to Cell & Gene therapy manufacturing

    Julie  Kerby

    Julie Kerby, Head of Process Industrialisation , Cell and Gene Therapy Catapult
    View Bio

  • Why manufacturing remains a significant challenge for cell and gene therapies
  • How Quality Target Product Profiles and process mapping techniques can be used to generate a process risk assessment and help you understand and accelerate your process development
     
  • 15:50 Harnessing CRISPR/Cas9 for drug development

    Emanuela Cuomo

    Emanuela Cuomo, Associate Director, AstraZeneca
    View Bio

    • Genome editing for target identification
    • Genome editing for cell model generation and target validation
    • Genome editing to understand drug resistance
    • Genome editing as a therapeutic
     

    16:30 Next-generation gene editing technology for allogeneic immune cell therapeutics

    Steven Kanner

    Steven Kanner, Chief Scientific Officer, Caribou Biosciences, Inc.
    View Bio

    • Next-generation CRISPR-Cas9 technology
    • Significantly enhanced editing specificity
    • Editing in immune cells for generation of functionally tuned therapeutics
     

    17:10 Chairman’s Closing Remarks and Close of Day One

    Pamela Tranter

    Pamela Tranter, Head of Translational Research Group, UCL
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Giuseppe Ronzitti

    Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon
    View Bio

    9:10 Spotlight: Advances in cell therapy process development and optimisation at Plasticell

    Yen Choo

    Yen Choo, Founder and Executive Chairman, Plasticell
    View Bio

    • Combinatorial screening of parameter space for process development and optimisation in cell and gene therapy
    • Expansion of hematopoietic stem cells from cord blood for allogeneic transplantation
    • Enhancement of viral transduction efficiency for autologous gene therapy to treat rare diseases
     

    9:50 Generation of endogenous reporter iPS cell lines for optimizing differentiation protocols, understanding disease biology & driving drug discovery projects

    Shailesh Gupta

    Shailesh Gupta, Senior Scientist, AstraZeneca PLC
    View Bio

    -    CRISPR/Cas9 in engineering iPS cells to generate cellular reagents for drug discovery.
    -    Clone screening capabilities/methodologies.
    -    Characterization, validation & potential application of PGE modified iPS cell lines.
     

    10:30 Morning Coffee

    11:00 Supporting advanced therapies - the Innovate UK perspective

    Ian McKay

    Ian McKay, Innovation Lead, Advanced Therapies, Innovate Uk
    View Bio

    • Support for advanced therapies – from Innovate UK and across Government
    • Innovate UK support for the commercialisation of advanced therapies
    • How the Advanced Therapy Treatment Centres will enable adoption of advanced therapies in the NHS
     

    11:40 Overcoming adeno-associated virus gene therapy limitations in genetic neuromuscular diseases

    Giuseppe Ronzitti

    Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon
    View Bio

    • Rare, genetic neuromuscular diseases constitute a bigger challenge given the absence of knowledge on the physiopatological mechanisms and of therapeutic options.
    • Adeno-associated virus (AAV) vector-based gene therapy became a principal actor in the development of therapies for monogenic diseases.
    • Successful human trials of gene transfer in the liver for hemophilia A and B, in the eye for congenital blindness and in the nervous system for spinal muscular atrophy have unveiled the therapeutic potential of this viral vector platform.
    • Development of technological tools to overcome the current limitations of AAV gene therapy applied to neuromuscular diseases.
     

    12:20 Networking Lunch

    13:20 Towards operational excellence in cell and gene therapy manufacturing and delivery

    Fabio D'Agostino

    Fabio D'Agostino, Partner, Alira Health
    View Bio

  • First generation processes in cell and gene therapy industry
  • 'Needle to Needle' challenges
  • Lean Six Sigma for advanced therapy medicinal products
  • 14:00 Accessing patients with commercial advanced therapies

    Diego Ardigo

    Diego Ardigo, R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A.
    View Bio

    • Addressing market access and reimbursement of advanced therapies (ATMPs)
    • Logistics and restricted access programs constraints in bringing ATMPs to patients in a commercial setting
    • Rare disease patient access with ATMPs
     

    14:40 Afternoon Tea

    15:10 GMP manufacture of plasmid DNA

    Paul Lloyd-Evans

    Paul Lloyd-Evans, Operations Manager, NHSBT
    View Bio

    • Good plasmid DNA manufacturing practice begins with an appropriate vector design. The eukaryotic promoter, gene sequence, and poly-A site primarily affect the therapeutic efficacy, remaining part of the vector is important for manufacturing
    • Choice of the plasmid’s origin of replication (ori) is critical for the plasmid copy number and for the cultivation titer. ColE1-derived, high copy-number pUC ori is widely established due to high copy number. Introduction of random or defined mutations into the pUC ori can further increase the plasmid yield.
    • Selecting appropriate host strain, maximizing titer by upstream optimization, and achieving superior performance in small- and large-scale cGMP manufacturing.
     

    15:50 Downstream benefits of DNA plasmids, plasmid delivery, and recent quality developments in plasmid manufacturing and testing

    EJ Brandreth

    EJ Brandreth, Vice President, Inovio Pharmaceuticals

    • DNA Plasmids have recently emerged as a potent new weapon, acting both as a therapeutic and as a vaccine
    • Plasmid GMP manufacturing, when compared to conventional mammalian and viral approaches, has notable benefits in compliance, cost and in facility throughput, and these will be explored
    • Recent advances in Plasmid testing, especially in light of current Plasmid guidance and recent assay developments, sheds a new light on today’s analytical approaches for process-related impurities, purity and potency for plasmids
     

    16:30 Scalable production of adult progenitor cell populations for skeletal regeneration – bridging the gap

    Ioannis Papantoniou

    Ioannis Papantoniou, ATMP Bioprocessing Coordinator, KU Leuven
    View Bio

    • Comparison across bioreactor systems -  visualization tools for bioprocess efficiency
    • Evaluation of functionality of expanded cell populations in small animal models – setting the target quality profiles
    • Development of real-time decision-making tools for optimising bioprocess management for high-risk autologous production
    • Adding a third dimension - controlling complexity in tissue engineered ATMPs
     

    17:10 Chairman’s Closing Remarks and Close of Day Two

    Giuseppe Ronzitti

    Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon
    View Bio

    +

    FEATURED SPEAKERS

    Diego Ardigo

    Diego Ardigo

    R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A.
    Emanuela Cuomo

    Emanuela Cuomo

    Associate Director, AstraZeneca
    Fabio D'Agostino

    Fabio D'Agostino

    Partner, Alira Health
    Giuseppe Ronzitti

    Giuseppe Ronzitti

    Cell and Gene Therapy Specialist, Genethon
    Ian McKay

    Ian McKay

    Innovation Lead, Advanced Therapies, Innovate Uk
    Janet Glassford

    Janet Glassford

    Quality Assessor , Medicines and Healthcare Products Regulatory Agency (MHRA)
    Julie  Kerby

    Julie Kerby

    Head of Process Industrialisation , Cell and Gene Therapy Catapult
    Kei Kishimoto

    Kei Kishimoto

    Chief Scientific Officer, Selecta Biosciences Inc.
    Lior  Raviv

    Lior Raviv

    Vice President of Development, Pluristem
    Mehdi  Gasmi

    Mehdi Gasmi

    Chief Science and Technology Officer, Adverum Biotechnology
    Pamela Tranter

    Pamela Tranter

    Head of Translational Research Group, UCL
    Peggy Sotiropoulou

    Peggy Sotiropoulou

    R&D Manager, Celyad
    Shailesh Gupta

    Shailesh Gupta

    Senior Scientist, AstraZeneca PLC
    Yen Choo

    Yen Choo

    Founder and Executive Chairman, Plasticell

    Diego Ardigo

    R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A.
    Diego Ardigo

    Dr. Ardigò is an MD (Internal Medicine) and obtained his PhD at the University of Parma (Italy) and his post-doctoral fellowship at Stanford University (California, US). Before joining the industry, he worked at the University of Parma (Italy) in the field of cardiovascular and metabolic genomics and as free-lance consultant for other academic institutions. He joined Chiesi in 2010, where acted as Clinical Lead in the registration of the first stem cell therapy in EU and led the cross-company team (with uniQure BV) treating the first patient with a commercial gene therapy in EU. He is currently the Head of the R&D Rare Disease Unit in Chiesi and chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and member of EBE-EFPIA ATMP Working Group. He is author of more than 40 indexed papers and speaker at international medical and industrial congresses.

    EJ Brandreth

    Vice President, Inovio Pharmaceuticals
    EJ Brandreth

    Emanuela Cuomo

    Associate Director, AstraZeneca
    Emanuela Cuomo

    Emanuela Cuomo is an Associate Director in the Discovery Biology department in Cambridge. She leads the Cell Biology team and co-leads the Precise genome editing discipline contributing to innovation in the CRISPR field. The Cell biology team generated cell models for target identification and validation for the Oncology disease area, including Immuno Oncology.


    Emanuela is an expert in the study of cell cycle signaling in normal and cancer cells.


    She obtained a PhD in biochemistry at the Institute of Cancer Research in London where she characterised a novel viral cyclin/CDK complex, its modulation by CDK inhibitors and its biological function in oncogenesis. Subsequently she joined UCL Cancer Institute in London in the Viral Oncogenesis team as a CR-UK postdoctoral fellow. There, she studied the interplay between the cellular DNA damage response and viral protein kinases.
     

    Fabio D'Agostino

    Partner, Alira Health
    Fabio D'Agostino


    Dr. Fabio D’Agostino brings extensive experience in cell and gene therapy to Alira Health. In 2013, he joined the Parenteral Drug Association (PDA) Cell and Gene Task Force (members include executives from GSK, Novartis, Lonza, Johnson & Johnson, Adaptimmune, Tigenix, Bluebird Bio) with the aim to develop a manufacturing control strategy for cell and gene based medicinal products. His areas of expertise also include Lean Six Sigma, process development and optimization, business development, technology evaluation.
     

    Fabio started his career at the medical device company Sorin Group (now LivaNova) after a BSc and a MSc with honors in Biomedical Engineering from the Polytechnic University of Turin (Italy). Later, he moved to Newcastle (UK) to take an Engineering Doctorate in Biopharmaceutical Process Development at Newcastle University.
     

    Giuseppe Ronzitti

    Cell and Gene Therapy Specialist, Genethon
    Giuseppe Ronzitti

    Dr. Ronzitti is group leader at Genethon. His main interest is the development of AAV-based gene therapies for rare diseases. In 2013, he arrived at Genethon as a post-doc supervised by Dr. Mingozzi to develop a gene therapy approach for Crigler-Najjar syndrome. This approach is now being translated in the clinic. Dr. Ronzitti then moved to the development of gene therapy approaches for glycogen storage diseases. An innovative gene therapy approach for Pompe disease is now in advanced clinical translation. Dr. Ronzitti is also recipient of a Marie Curie fellowship for the development of gene therapy for GSDIII a neuromuscular glycogenosis.

    Ian McKay

    Innovation Lead, Advanced Therapies, Innovate Uk
    Ian McKay

    Ian joined Innovate UK from the Department of Health (DH) where he was the policy lead for stem cell transplantation and advanced therapies. At DH was part of a high profile policy team with a broad scientific remit that included; rare diseases, genomics and emerging technologies. Before joining the DH he was a health and science policy adviser for the British Dental Association. He began his career as a lecturer in cell and molecular biology at Queen Mary, University of London. Ian has a PhD in Developmental Biology.

    Ioannis Papantoniou

    ATMP Bioprocessing Coordinator, KU Leuven
    Ioannis Papantoniou

    Ioannis Papantoniou is A Chemical Engineer by training, at the University of Patras, Greece. After graduation he pursued a Doctoral degree (MPhil and PhD) at the Department of Biochemical Engineering, University College London (UCL), UK. He carried out his postdoctoral research activities first at UCL and subsequently at KU Leuven working on bioprocess optimization for prostate cancer cell therapy vaccine production (a precursor of CAR-T cell therapies), in collaboration with Onyvax and skeletal ATMP bioprocess development respectively. Currently he is leading several academic research projects and collaborative R&D activities with several industrial partners active in the cell therapy and tissue engineering, biosensor, and bioreactor sectors. His research aim is to develop automated, scalable and cost-effective bioprocess pipelines for the production of compliant 3D Tissue Engineered ATMPs with built-in quality attributes.

    Janet Glassford

    Quality Assessor , Medicines and Healthcare Products Regulatory Agency (MHRA)
    Janet Glassford

    Janet Glassford is a Senior Quality Assessor at the MHRA and an EMA expert, with a special interest in ATMPS. Her role includes assessment of ATMP marketing authorisations, as well as the provision of EMA and MHRA scientific advice and innovation queries. Prior to becoming a regulator, she was an academic fellow at University College London with a research interest in the cell biology of haematological malignancies.

    Julie Kerby

    Head of Process Industrialisation , Cell and Gene Therapy Catapult
    Julie  Kerby

    Julie Kerby is Head of Process Industrialisation at the Cell and Gene Therapy Catapult.


    Julie has more than 20 years’ experience across large pharma, biotech and academic laboratories, including 7 years at Pfizer Ltd as Biology Lead for a cell replacement therapy for Age Related Macular Degeneration which achieved First-in-Human in 2015. Working closely with our collaborators she is responsible for the development and technical transfer of cell and gene therapy manufacturing processes ensuring they meet quality and regulatory requirements.

    Julie holds a BSc. Hons degree in Biology from the University of Southampton
     

    Kei Kishimoto

    Chief Scientific Officer, Selecta Biosciences Inc.
    Kei Kishimoto

    Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

    Lior Raviv

    Vice President of Development, Pluristem
    Lior  Raviv

    Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development. Prior to that Mr. Raviv served as Process development engineer and Projects manager & Product development Team leader at Pluristem in charge of new technologies and process development. Prior to joining Pluristem and during the years 2010-2011, Mr Raviv held the position of R&D Analytical Researcher at Teva Pharmaceutical Industries. Mr. Raviv holds a M.Med.Sec in pharmacology from the Ben Gurion University and a B.S.c, in Biotechnology engineering from the Ben Gurion University.

    Mehdi Gasmi

    Chief Science and Technology Officer, Adverum Biotechnology
    Mehdi  Gasmi

    Mehdi Gasmi, Ph.D. is Adverum’s chief science and technology officer. He joined the Company in 2013 and leads process development, manufacturing, and quality control functions for Adverum’s gene therapy product candidates. He is also responsible for the development of Adverum’s novel vector technology platform. A gene therapy veteran, Dr. Gasmi has worked in the field since 1996 at various academic institutions, including City of Hope and the University of California, San Diego, and at gene therapy companies, including Chiron, Cell Genesys, and Ceregene. Dr. Gasmi has extensive experience in the design, development and manufacturing of lentiviral and recombinant AAV vectors for clinical applications. Prior to Adverum, Dr. Gasmi was vice president of biomanufacturing at Généthon. He received a M.S. and Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.

    Pamela Tranter

    Head of Translational Research Group, UCL
    Pamela Tranter

    Pamela joined the UCL Translational Research Office in Nov 2014 and became head of the Translational Research group in Sept 2016. The TRO builds on an increasingly vibrant translational culture across UCL by collaboration with academics, industry partners and external funding bodies, to facilitate the translation of UCL’s emerging research into therapies and medical products. Pamela has advised and supported successful applications for cell and gene therapy projects which she is now managing in both the pre-clinical and early clinical phases.

    Prior to this Pamela gained extensive experience of drug discovery in the pharmaceutical industry at Novartis/Ciba-Geigy. She has led projects for multiple small molecule and Biologics targets for respiratory and thrombosis indications.
     

    Paul Lloyd-Evans

    Operations Manager, NHSBT
    Paul Lloyd-Evans

    Head of NHSBT’s Clinical Biotechnology Centre since 2007 and responsible for the day to day management of the facility. The CBC is part of NHSBT’s Cell and Molecular Therapies function and specialises in the small scale GMP manufacture of clinical grade gene therapy such as plasmid DNA and recombinant protein products. Graduated in 1984 before undertaking a PhD in Immunology and further post-doctoral studies. In 1993 joined NHSBT in antibody engineering and became the development scientist at the CBC in 2001. To date publications include 24 peer-reviewed papers and articles.

    Peggy Sotiropoulou

    R&D Manager, Celyad
    Peggy Sotiropoulou

    Peggy Sotiropoulou is R&D Manager in Celyad, in charge of developing the new strategies in CAR T cell design. Peggy is an expert in tumour initiation, growth and resistance to therapy, tumour microenvironment and cancer stem cells. She has a 17-year career in academic research in oncology, holding an associate Professor position in the Université Libre de Bruxelles, in Brussels, Belgium. Peggy decided to join Celyad in 2017 to translate cutting-edge research and innovation into actual treatments for patients.

    Shailesh Gupta

    Senior Scientist, AstraZeneca PLC
    Shailesh Gupta

    Shailesh is Associate Principle Scientist in Discovery Sciences iMED, AstraZeneca based in Sweden. Shailesh has been using CRISPR/Cas9 and human iPS cells to generate cellular models to understand disease biology and drive drug discovery projects in cardiovascular, metabolic & CNS diseases. Before joining AstraZeneca Shailesh was in Singapore, working for GlaxoSmithKline (GSK), in a group that was focused on modeling CNS diseases & developing novel assays using Stem Cells & iPSCs. Shailesh has a strong background in genome editing, cell based high content small molecule screening, assay development and human stem cells/iPSCs based disease modeling. Previous to his position at GSK, Shailesh was postdoc at Harvard University performing research focused on developing novel therapeutics for ALS disease through high content small molecule screen using motor neurons derived from embryonic stem cells. Shailesh has a PhD in developmental neuroscience

    Steven Kanner

    Chief Scientific Officer, Caribou Biosciences, Inc.
    Steven Kanner

    Steve Kanner is the Chief Scientific Officer of Caribou Biosciences responsible for the Company’s therapeutic discovery and R&D activities. Before joining Caribou, Steve was Vice President, Head of Biology at Arrowhead Pharmaceuticals, and worked in oncology and immunology drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 80 publications, and is an inventor on numerous U.S. and foreign patents. Steve earned his undergraduate degree in Genetics from the University of California, Berkeley, and his Ph.D. in Immunology and Microbiology from the University of Miami School of Medicine. His post-doctoral fellowship was at the University of Virginia.

    Yen Choo

    Founder and Executive Chairman, Plasticell
    Yen Choo

    Dr Choo is Executive Chairman of Plasticell Ltd and Chief Executive of Progenitor Labs Ltd. He is the founder of Plasticell and served as Chief Executive and Chief Scientist of the company. Prior to his interest in stem cells he was a founder and Chief Scientist of Gendaq (acquired by Sangamo Biosciences), a biotech company that developed the zinc finger technology now used for gene editing. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge, where he pioneered the engineering of protein-DNA interactions using combinatorial methods under Nobel laureate Sir Aaron Klug. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge and for his thesis received the Prize for Young Scientists awarded by GE Healthcare and Science (1996), and the Max Perutz Student Prize awarded by MRC-LMB (1995). He sits on the UK Stem Cell Steering Committee which oversees national stem cell research and the UK Stem Cell Bank.

    Supporters

    Workshops

    Practicalities in the Development of Stem Cell Therapies
    Workshop

    Practicalities in the Development of Stem Cell Therapies

    Copthorne Tara Hotel
    9th October 2018
    London, United Kingdom

    Strategic Competitive Intelligence in the Cell and Gene Therapy space
    Workshop

    Strategic Competitive Intelligence in the Cell and Gene Therapy space

    Copthorne Tara Hotel
    9th October 2018
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    [SPEAKERS 2018] - FULL LIST OF SPEAKERS

    Download

    [Chair's Letter 2018] - Pamela Tranter, UCL

    Download

    [SPEAKER INTERVIEW] - Peggy Sotiropoulou, Ceylad

    Download

    [SPEAKER INTERVIEW] - IOANNIS PAPANTONIOU, KU Leuven

    Download

    [DAY 2] - FULL PROGRAMME

    Download

    [WORKSHOP B] - FULL DETAILS

    Download

    [DAY 1] - FULL PROGRAMME

    Download

    [WORKSHOP A] - FULL DETAILS

    Download

    [FULL BROCHURE] - 2018

    Download

    [PRESS RELEASE 1] - Discover the World of ATMPs

    Download

    Media Partners


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets

    Supporters
    http://www.JforCS.com

    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    EIN News

    Supporters
    http://www.einnews.com

    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


    Gene Therapy Net

    Supporters
    http://www.genetherapynet.com


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out